(2003) reported similar frequencies of MEFV mutations among primary progressive (PP) and relapsing–remitting (RR) MS patients within European Jewish (Ashkenazi), Iraqi Jewish, and North-African Jewish populations. Here, MEFV is linked to myeloid sarcoma.